Arvinas Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Randy Teel

Geschäftsführender

US$3.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	12.58%
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Recent updates

Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Jan 27

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Nov 24

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Sep 09

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Jun 01

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

May 01

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Mar 24 Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Mar 14

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Mar 12

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Randy Teel im Vergleich zu den Einnahmen von Arvinas verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2025	n/a	n/a	-US$58m
Jun 30 2025	n/a	n/a	-US$73m
Mar 31 2025	n/a	n/a	-US$47m
Dec 31 2024	US$4m	US$475k	-US$199m

Vergütung im Vergleich zum Markt: RandyDie Gesamtvergütung ($USD3.78M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.30M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Randy mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Randy Teel (45 yo)

no data

Amtszeit

US$3,776,333

Vergütung

Dr. Randy Teel, Ph.D. served as Interim Chief Financial Officer and Treasurer at Arvinas, Inc. since February 29, 2024 until April 2024 and served as its Chief Business Officer since April 2024 until Febru...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Randy Teel	CEO, President & Director	no data	US$3.78m	0.062% $ 477.0k
Andrew Saik	CFO & Treasurer	1.7yrs	US$3.72m	0.026% $ 201.3k
Angela Cacace	Chief Scientific Officer	1.7yrs	US$2.97m	0.052% $ 397.0k
Noah Berkowitz	Chief Medical Officer	1.9yrs	US$6.10m	0.024% $ 183.7k
David Loomis	VP & Chief Accounting Officer	no data	keine Daten	0.012% $ 89.6k
Jeff Boyle	Vice President of Investor Relations	5.1yrs	keine Daten	keine Daten
Jared Freedberg	General Counsel & Corporate Secretary	2.1yrs	keine Daten	keine Daten
Steve Weiss	Senior VP & Chief Human Resources Officer	no data	keine Daten	keine Daten
Lisa Sinclair	Senior Vice President of Corporate Operations	3.5yrs	keine Daten	keine Daten
Paul McInulty	Senior Vice President of Regulatory Affairs	3.3yrs	keine Daten	keine Daten
Alexander Santini	Interim Chief Commercial Officer & Senior VP of Global and U.S. Market Access	no data	keine Daten	keine Daten
Kelly Page	Senior VP & Global Head of Oncology Strategy and Program Leadership	2.9yrs	keine Daten	keine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: ARVNDas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Randy Teel	CEO, President & Director	no data	US$3.78m	0.062% $ 477.0k
Edward Kennedy	Independent Director	7.6yrs	US$451.53k	0.082% $ 632.4k
Lillian Siu	Member of Scientific Advisory Board	6.3yrs	keine Daten	keine Daten
Leslie Norwalk	Independent Director	6.6yrs	US$451.53k	0.016% $ 120.1k
Briggs Duncan W. Morrison	Chairman & Lead Director	7.7yrs	US$480.39k	0.093% $ 719.4k
Laurie Smaldone Alsup	Independent Director	6.3yrs	US$456.53k	0.016% $ 120.1k
Adam Boxer	Member of Scientific Advisory Board	6.3yrs	keine Daten	keine Daten
Lennart Mucke	Member of Scientific Advisory Board	6.3yrs	keine Daten	keine Daten
Benjamin Neel	Member of Scientific Advisory Board	6.3yrs	keine Daten	keine Daten
Linda Bain	Independent Director	5.7yrs	US$461.53k	0.016% $ 120.1k
John Houston	Director	8.4yrs	US$12.75m	1.42% $ 10.9m
Ian Taylor	Chairman of Scientific Advisory Board	1.1yrs	US$4.22m	0.18% $ 1.4m

6.3yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ARVNDie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/02/23 15:42
Aktienkurs zum Tagesende	2026/02/23 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Informationen über das Analysemodell, das für die Erstellung dieses Berichts verwendet wurde, findest du auf unserer Github-Seite. Außerdem haben wir Anleitungen zur Nutzung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Arvinas, Inc. wird von 28 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Peter Lawson	Barclays
Etzer Darout	Barclays
Tazeen Ahmad	BofA Global Research

Arvinas Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Arvinas, Inc. Announces Management Changes

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President

Insufficient new directors

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025

Arvinas, Inc., Annual General Meeting, Jun 25, 2025

Insider recently sold US$74k worth of stock

Recent updates

Arvinas, Inc. to Report Q4, 2025 Results on Feb 24, 2026

Arvinas, Inc. Announces Management Changes

Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Price target decreased by 32% to US$12.44

Arvinas, Inc. Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab At the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Arvinas, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Arvinas, Inc. Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-Mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Arvinas, Inc. Announces New Patient-Reported Outcomes (PRO) Data from the Phase 3 Veritac-2 Clinical Trial Evaluating Vepdegestrant

Arvinas, Inc. Presents Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Arvinas, Inc. Approves Reduction in Workforce of Approximately 15% Across Roles in Functional Areas of the Company Primarily Related to Vepdegestrant Commercialization

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President

Insufficient new directors

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc.

Arvinas, Inc. Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Price target decreased by 7.9% to US$34.24

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

Arvinas, Inc., Annual General Meeting, Jun 25, 2025

Arvinas, Inc. to Report Q1, 2025 Results on May 01, 2025

Arvinas Announces Results from the Veritac-2 Trial Selected as Late-Breaking Oral Presentation At the 2025 American Society of Clinical Oncology Annual Meeting

Price target decreased by 8.9% to US$39.47

Arvinas, Inc. Presents First-In-Human Data for Investigational Oral Protac ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Insider recently sold US$74k worth of stock

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Price target decreased by 18% to US$50.05

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

New major risk - Share price stability

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Chairperson recently sold US$524k worth of stock

Consensus EPS estimates upgraded to US$3.69 loss

Full year 2024 earnings: EPS exceeds analyst expectations

Arvinas, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Arvinas, Inc. Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Arvinas and Pfizer Announces Initial Phase 1B Data from the Tactive-U Sub-Study of Vepdegestrant in Combination with Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Consensus revenue estimates increase by 20%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors